{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:10:11Z","timestamp":1793398211238,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008678","name":"Universit\u00e4t Leipzig","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008678","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ciltacabtagene autoleucel (cilta-cel) is a BCMA-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed or refractory multiple myeloma (RRMM). Following the CARTITUDE-1 results in heavily pretreated patients, the randomized phase 3 CARTITUDE-4 trial demonstrated superior progression-free survival (PFS) and overall survival for cilta-cel compared with standard of care in lenalidomide-refractory patients after one to three prior lines, leading to label expansion in 2024. However, real-world data characterizing outcomes in this earlier-line indication are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed all patients with RRMM receiving standard-of-care cilta-cel between 2022 and 2025 from the German Registry for Stem Cell Transplantation and Cellular Therapy. Patients were stratified by prior lines of therapy into an Early group (1\u20133 prior lines) and a Late group (&gt;\u20093 prior lines). The primary endpoint was PFS. Secondary endpoints included overall response rate, response conversion, and safety outcomes including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome (ICANS), non-ICANS neurotoxicity, and non-relapse mortality. Prognostic associations were assessed using restricted cubic spline Cox regression and univariable Cox models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 606 patients, 177 (30%) were treated in the Early and 429 (70%) in the Late setting. The overall response rate was 91% and 88%, with complete response in 63% and 54%, respectively. The 12-month PFS was 79% for Early and 70% for Late cilta-cel. Depth of response was the strongest predictor of PFS in both cohorts, with patients maintaining complete response showing 100% PFS at 12 months irrespective of treatment line. Extramedullary disease was adversely prognostic in both groups, whereas high-risk cytogenetics were not associated with inferior PFS in the Early group. Non-ICANS neurotoxicity occurred less frequently in the Early group (3% versus 8%), while non-relapse mortality was comparable (6% versus 7%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This analysis demonstrates that cilta-cel in earlier lines of therapy achieves deep responses and high PFS consistent with the CARTITUDE-4 trial. These results provide real-world evidence for the deployment of cilta-cel as early as first relapse and may be a benchmark outside prospective trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-026-01806-6","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:55:31Z","timestamp":1779299731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis"],"prefix":"10.1186","volume":"19","author":[{"given":"Nico","family":"Gagelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Flossdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samih","family":"Smaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Metzeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bullinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus","family":"Duyster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Christian","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Teipel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Alsdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lengerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Schub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis Ayuketang","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Bassermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schultze-Florey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schroers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Giesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Elmaagacli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Burchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Mougiakakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy, DRST","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"1806_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos M-V, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023;389:335\u201347.","journal-title":"N Engl J Med"},{"key":"1806_CR2","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S1470-2045(25)00653-9","volume":"27","author":"H Einsele","year":"2026","unstructured":"Einsele H, San-Miguel J, Dhakal B, Touzeau C, Leleu X, Donk NW, van de, et al. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2026;27:254\u201368.","journal-title":"Lancet Oncol"},{"key":"1806_CR3","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1182\/blood-2025-2215","volume":"146","author":"B Dhakal","year":"2025","unstructured":"Dhakal B, Iida S, Sidiqi MH, Zamagni E, Yoon S-S, Callander N, et al. Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma. Blood. 2025;146:2215.","journal-title":"Blood"},{"key":"1806_CR4","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1200\/JCO-24-01730","volume":"43","author":"DK Hansen","year":"2025","unstructured":"Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, et al. Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed\/Refractory Multiple Myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 2025;43:1597\u2013609.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1806_CR5","doi-asserted-by":"publisher","first-page":"e70070","DOI":"10.1002\/hem3.70070","volume":"9","author":"M Merz","year":"2025","unstructured":"Merz M, Albici A-M, von Tresckow B, Rathje K, Fenk R, Holderried T, et al. Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study. HemaSphere. 2025;9:e70070.","journal-title":"HemaSphere"},{"key":"1806_CR6","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1182\/blood.2025028330","volume":"146","author":"M Merz","year":"2025","unstructured":"Merz M, Gagelmann N, Smaili S, Flossdorf S, Sauer S, Scheid C, et al. Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST. Blood. 2025;146:1677\u201386.","journal-title":"Blood"},{"key":"1806_CR7","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"1806_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl"},{"key":"1806_CR9","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41:1265\u201374.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1806_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet Lond Engl. 2021;398:314\u201324.","journal-title":"Lancet Lond Engl"},{"key":"1806_CR11","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","volume":"43","author":"S Jagannath","year":"2025","unstructured":"Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, et al. Long-Term (\u2265\u20095-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed\/Refractory Multiple Myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 2025;43:2766\u201371.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1806_CR12","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1182\/blood-2025-2291","volume":"146","author":"T Sebastian","year":"2025","unstructured":"Sebastian T, Hashmi H, Firestone R, Jurgens E, Rajeeve S, Farzana T, et al. Functionally high-risk disease is associated with inferior outcomes after chimeric antigen receptor T-cell therapy for relapsed refractory multiple myeloma. Blood. 2025;146:2291.","journal-title":"Blood"},{"key":"1806_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1182\/blood-2025-92","volume":"146","author":"S Parekh","year":"2025","unstructured":"Parekh S, Li K, Van De Donk NWCJ, Lin Y, Martin T, Han S, et al. Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study. Blood. 2025;146:92.","journal-title":"Blood"},{"key":"1806_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41408-024-01049-z","volume":"14","author":"J Richter","year":"2024","unstructured":"Richter J. Like a bridge over troubled water: keeping the myeloma down en route to CAR-T. Blood Cancer J. 2024;14:64.","journal-title":"Blood Cancer J"},{"key":"1806_CR15","doi-asserted-by":"crossref","unstructured":"Cohen AD, Parekh S, Santomasso BD, G\u00e1llego P\u00e9rez-Larraya J, van de Donk NWCJ, Arnulf B, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12:32.","DOI":"10.1038\/s41408-022-00629-1"},{"key":"1806_CR16","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41591-025-04121-8","volume":"32","author":"M Ho","year":"2026","unstructured":"Ho M, Paruzzo L, Noll JH, Stella F, Devi P, Ndeupen S, et al. CD4\u2009+\u2009T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy. Nat Med. 2026;32:702\u201316.","journal-title":"Nat Med"},{"key":"1806_CR17","doi-asserted-by":"crossref","unstructured":"Rade M, Fandrei D, Kreuz M, Seiffert S, Grahnert A, Friedrich M et al. A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma. Cancer Cell 2026;44(3):586\u2013603.","DOI":"10.1016\/j.ccell.2025.10.014"},{"key":"1806_CR18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1182\/blood-2025-96","volume":"146","author":"H Hosoya","year":"2025","unstructured":"Hosoya H, Velayati A, Dima D, Jensen A, Portuguese A, Hovanky V, et al. Rapid peak CAR-T expansion is associated with delayed neurotoxicity following ciltacabtagene autoleucel in multiple myeloma. Blood. 2025;146:96.","journal-title":"Blood"},{"key":"1806_CR19","doi-asserted-by":"publisher","first-page":"7522","DOI":"10.1200\/JCO.2025.43.16_suppl.7522","volume":"43","author":"KJC Lim","year":"2025","unstructured":"Lim KJC, Parrondo RD, Chhabra S, Dooley K, De Menezes Silva Corraes A, Gertz MA, et al. Investigating the association between peak post-infusion absolute lymphocyte count (ALC) and delayed toxicity in myeloma (MM) patients (pts) receiving cilta-cel. J Clin Oncol. 2025;43:7522\u20137522.","journal-title":"J Clin Oncol"},{"key":"1806_CR20","doi-asserted-by":"crossref","unstructured":"Jurgens EM, Mitra S, Herrera K, Nemirovsky D, Bready B, Derkach A et al. Robust CD4\u2009+\u2009CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel. MedRxiv Prepr Serv Health Sci 2025;2025.10.28.25338924.","DOI":"10.1101\/2025.10.28.25338924"},{"key":"1806_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41408-025-01410-w","volume":"15","author":"P Rodr\u00edguez-Otero","year":"2025","unstructured":"Rodr\u00edguez-Otero P, Sidana S, Kouwenhoven M, Schecter JM, Lendvai N, De Braganca KC, et al. Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed\/refractory MM in CARTITUDE-1, -2, and \u2013\u20094. Blood Cancer J. 2025;15:209.","journal-title":"Blood Cancer J"},{"key":"1806_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","volume":"17","author":"S Zanwar","year":"2024","unstructured":"Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, et al. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. J Hematol OncolJ Hematol Oncol. 2024;17:42.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"1806_CR23","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1200\/JCO.23.02232","volume":"42","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, et al. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed\/Refractory Multiple Myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 2024;42:1665\u201375.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1806_CR24","doi-asserted-by":"publisher","first-page":"e70159","DOI":"10.1002\/hem3.70159","volume":"9","author":"P Born","year":"2025","unstructured":"Born P, Fandrei D, Wang SY, Perez-Fernandez C, Fischer L, Ussmann J, et al. Prognostic significance of PET\/CT for CAR T cell therapy in relapsed\/refractory multiple myeloma. HemaSphere. 2025;9:e70159.","journal-title":"HemaSphere"},{"key":"1806_CR25","doi-asserted-by":"publisher","first-page":"e635","DOI":"10.1016\/S2352-3026(25)00117-6","volume":"12","author":"NWCJ van de Donk","year":"2025","unstructured":"van de Donk NWCJ, Moreau P, San-Miguel JF, Mateos M-V, Dimopoulos MA, Zweegman S, et al. Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network. Lancet Haematol. 2025;12:e635\u201349.","journal-title":"Lancet Haematol"},{"key":"1806_CR26","doi-asserted-by":"crossref","unstructured":"van de Donk NWCJ, Sonneveld P, Einsele H. Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape. Blood 2026;blood.2025032536.","DOI":"10.1182\/blood.2025032536"},{"key":"1806_CR27","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2406536","volume":"392","author":"YC Cohen","year":"2025","unstructured":"Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min C-K, et al. Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2025;392:138\u201349.","journal-title":"N Engl J Med"},{"key":"1806_CR28","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1182\/blood-2025-699","volume":"146","author":"A Cohen","year":"2025","unstructured":"Cohen A, Susanibar-Adaniya S, Garfall A, Vogl D, Kapur S, Waxman A, et al. Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy: preliminary safety, efficacy, and correlative data from the STEM (Sequential T Cell-Engagement for Myeloma) trial. Blood. 2025;146:699.","journal-title":"Blood"},{"key":"1806_CR29","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1182\/blood.2025029773","volume":"146","author":"B Dhakal","year":"2025","unstructured":"Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, et al. Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. Blood. 2025;146:2063\u201372.","journal-title":"Blood"},{"key":"1806_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/2643-3230.BCD-24-0118","volume":"6","author":"D Fandrei","year":"2025","unstructured":"Fandrei D, Seiffert S, Rade M, Rieprecht S, Gagelmann N, Born P, et al. Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed\/Refractory Multiple Myeloma. Blood Cancer Discov. 2025;6:38\u201354.","journal-title":"Blood Cancer Discov"},{"key":"1806_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","volume":"11","author":"TM Schmidt","year":"2021","unstructured":"Schmidt TM, Fonseca R, Usmani SZ. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J. 2021;11:83.","journal-title":"Blood Cancer J"},{"key":"1806_CR32","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","volume":"39","author":"LJ Costa","year":"2025","unstructured":"Costa LJ, Banerjee R, Mian H, Weisel K, Bal S, Derman BA, et al. International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025;39:543\u201354.","journal-title":"Leukemia"},{"key":"1806_CR33","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1182\/blood-2025-2411","volume":"146","author":"R Bowden","year":"2025","unstructured":"Bowden R, Araque J, Choudhary G, Kallenbach L, Alegria V, Costa O, et al. Ciltacabtagene autoleucel out-of-specification manufacturing outcomes improve with earlier lines of therapy. Blood. 2025;146:2411.","journal-title":"Blood"},{"key":"1806_CR34","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1056\/NEJMoa2514663","volume":"394","author":"LJ Costa","year":"2026","unstructured":"Costa LJ, Bahlis NJ, Perrot A, Nooka AK, Lu J, Pawlyn C, et al. Teclistamab plus daratumumab in relapsed or refractory multiple myeloma. N Engl J Med. 2026;394:739\u201352.","journal-title":"N Engl J Med"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01806-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01806-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01806-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:20:18Z","timestamp":1782400818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01806-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1806"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01806-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Determined by the national registry and approval by the board. Every patient gave informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N.G.: Adboard and Travel support: JnJ, BMS, GSK, Stemline, Pfizer, Medac, Kite\/Gilead.M.M. is supported by research grants from the European Commission (CERTAINTY), Jose Carreras Leukemia Foundation, the International Myeloma Society and theHector Foundation. Honoraria: Janssen, BMS GmbH & Co KG, Amgen, Abbvie, Stemline Therapeutics, Takeda, Sanofi, Pfizer. Consulting or Advisory Role: Janssen, BMS GmbH & Co KG, Pfizer, Sanofi. Research Funding: Janssen, SpringWorks Therapeutics, Roche\/Genentech. Travel, Accommodations, Expenses: Janssen, Stemline Therapeutics, Pfizer. Kite\/Gilead. M.M. is supported by research grants from the European Commission (CERTAINTY), Jose Carreras Leukemia Foundation, the International Myeloma Society and the Hector Foundation. Honoraria: Janssen, BMS GmbH & Co KG, Amgen, Abbvie, Stemline Therapeutics, Takeda, Sanofi, Pfizer. Consulting or Advisory Role: Janssen, BMS GmbH & Co KG, Pfizer, Sanofi. Research Funding: Janssen, SpringWorks Therapeutics, Roche\/Genentech. Travel, Accommodations, Expenses: Janssen, Stemline Therapeutics, Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}